United Kingdom,United States : Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Source :: Mena Report. December 22, 2016
Publication Year :: 2016
Abstract: Bristol-Myers Squibb Company and Calithera Biosciences, Inc, a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for [...]

Subjects :: Bristol-Myers Squibb Co.
Cancer treatment -- Physiological aspects
Glutamine -- Physiological aspects
Medical research -- Physiological aspects
Biotechnology industries -- Physiological aspects
Pharmaceutical industry -- Physiological aspects
Renal cell carcinoma -- Physiological aspects
Business, international
Opdivo (Medication)

Tools